EGFR-TKI plus antiangiogenic agent combination therapy may reduce the incidence of EGFR-TKI-associated interstitial lung disease in Asian

Kaohsiung J Med Sci. 2022 Nov;38(11):1133-1134. doi: 10.1002/kjm2.12584. Epub 2022 Aug 26.

Authors

Tai-Huang Lee¹, Hsiao-Ling Chen², Ming-Ju Tsai³, Chih-Jen Yang^{3

4}

Affiliations

¹ Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
² Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
³ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
⁴ School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

PMID: 36053872
DOI: 10.1002/kjm2.12584

No abstract available

Publication types

Letter

MeSH terms

Angiogenesis Inhibitors / adverse effects
ErbB Receptors / genetics
Humans
Incidence
Lung Diseases, Interstitial* / chemically induced
Lung Diseases, Interstitial* / drug therapy
Lung Neoplasms* / drug therapy
Mutation
Protein Kinase Inhibitors / adverse effects

Substances

Angiogenesis Inhibitors
ErbB Receptors
Protein Kinase Inhibitors
EGFR protein, human